Aaron Cowen’s Heron Therapeutics HRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-2,807,000
Closed -$11.8M 94
2022
Q3
$11.8M Sell
2,807,000
-444,048
-14% -$1.74M 0.49% 46
2022
Q2
$9.07M Buy
3,251,048
+382,000
+13% +$1.53M 0.34% 58
2022
Q1
$16.4M Buy
2,869,048
+382,708
+15% +$2.8M 0.5% 50
2021
Q4
$22.7M Buy
2,486,340
+995,900
+67% +$10.2M 0.44% 49
2021
Q3
$15.9M Hold
1,490,440
0.27% 54
2021
Q2
$23.1M Buy
1,490,440
+984,403
+195% +$15.7M 0.35% 58
2021
Q1
$8.2M Buy
+506,037
New +$9.02M 0.12% 79
2020
Q2
Sell
-40,500
Closed -$475K 93
2020
Q1
$475K Buy
+40,500
New +$761K 0.01% 62

Other funds holding HRTX

Aaron Cowen's HRTX Position: Q4 2022 in Review

Aaron Cowen sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 2,807,000 shares — an estimated $11.8M sold.

Aaron Cowen first reported a position in HRTX in Q1 2020 and held it in 8 quarters. The position peaked at $23.1M in Q2 2021. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

  • Aaron Cowen reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Aaron Cowen sold 2,807,000 Heron Therapeutics shares in Q4 2022, an estimated $11.8M.
  • Aaron Cowen first reported a position in Heron Therapeutics in Q1 2020 and held it in 8 quarters.
  • Aaron Cowen's Heron Therapeutics position peaked at $23.1M in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Suvretta Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.